Podcasts about Bayer

Wir haben zwei Probleme: Erik ten Hag wurde erst nach unserer Aufnahme offiziell neuer Leverkusen-Trainer. Und Ole Werner hat sich auch erst danach dazu entschieden, Werder Bremen nächstes Jahr zu verlassen. Wir haben aber trotzdem ausführlich über die Bundesliga gesprochen: Über den Pokalsieger VfB Stuttgart, über den FC Bayern nach der Absage von Florian Wirtz und den FC Augsburg, der an Sandro Wagner baggert. Außerdem: Wie gut spielt eigentlich der schottische Goretzka in Neapel? Und war das nicht insgesamt eine geile Saison? Hört rein und diskutiert gerne mit!

Zwei News kamen zu spät für die heutige Folge: Ten Hag ist jetzt offiziell bei Leverkusen und Ole Werner verlässt Werder 2026. Trotzdem gibt's viel Bundesliga auf die Ohren: Pokalsieger Stuttgart, Wirtz' Bayern-Absage und der Wagner-Flirt in Augsburg.

Die Themen: Norweger wacht mit Containerschiff im Garten auf; SPD muss Otto-Wels-Saal nicht an AfD abgeben; Merkel kritisiert Grenzkontrollen; Jeder Vierte hat Einwanderungsgeschichte; Harvard darf keine ausländischen Studenten mehr aufnehmen; Getöteter Botschaftsmitarbeiter Israels war Bayer; Rheingold-Studie sieht Verbundenheitskrise; Hohe Erwartungen an Berlins neue Kultursenatorin und Kim Kardashian ist jetzt offiziell Anwältin. Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/ApokalypseundFilterkaffee

Mais um VACILO NEWS no ar! E hoje Daniel Bayer e João Carvalho te deixam super informado a respeito de carros sexualmente vulneráveis, casamentos de diversão e araras fumantes!FINANCIE ESTE VACILO:apoia.se/decrepitosAssine o plano BOGA VIVA e participe do nosso GRUPO SECRETO NO TELEGRAM!MANDA PIX:livepix.gg/decrepitosPARTICIPE PELO E-MAIL:ouvinte@decrepitos.comANUNCIE COM A GENTE:comercial@decrepitos.com

Ed Bushaw joins us to discuss the upcoming Knights of Columbus Boston Butt sale, Andrea Picotti-Bayer on three compelling Catholic court cases, and Dr. Matthew Brunson on his new biography on Pope Leo XIV.

This episode covers: Cardiology This Week: A concise summary of recent studies The role of cardiac magnetic resonance in myocardial disease Air pollution and heart disease Statistics Made Easy: Quasi-experimental study designs Host: Rick Grobbee Guests: Carlos Aguiar, Steffen Petersen, Mark Miller Want to watch that episode? Go to: https://esc365.escardio.org/event/1806 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Mark Miller have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Steffen Petersen Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1806?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

While few doubt the opportunity represented by real-world evidence, some concerns remain about its validity compared to traditional forms of clinical evidence, particularly among regulators. To address these concerns, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, suggests that incorporating some elements of traditional trials, such as randomization, is a good way to persuade regulators that RWE can be used for consumer health innovation, for example in generating new claims or supporting Rx-to-OTC switch. Looking forward, Spitzer is excited about the ways in which digital health tools and artificial intelligence can be used to expand the scope of RWE as well as drive personalization for consumers. Timestamps: 3:00 - Addressing concerns about RWE's scientific rigour and validity 12:00 – Regulators' views of RWE, particularly for consumer health 16:00 – Use of RWE for Rx-to-OTC switch 22:00 – The future of RWE Guest Bio: Volker Spitzer has more than 30 years of R&D experience spanning the consumer health sector, ingredients industry, and academia. Beginning his career as a professor in pharmaceutical sciences, he ascended to global positions encompassing R&D, innovation, licensing/M&A, and medical marketing at firms like Roche, DSM Nutritional Products, and Bayer. Since October 2017, Spitzer has been affiliated with IQVIA Consumer Health, serving as the vice president for global R&D and RWE Services. His purview primarily includes clinical research, RWE, virtual trials, and the burgeoning field of digital health. He has penned over 80 scientific publications, whitepapers and textbooks centered on science and innovation.

Die Zeitzeugin von Zwangsarbeit und späteres Fotomodell Irma Frei trifft in der Sendung "Persönlich" auf den Pianisten Matthias Schulz, künftiger Intendant des Opernhauses Zürich. Das Gespräch führt Olivia Röllin. Matthias Schulz (47) wird ab kommendem Herbst neuer Intendant des Opernhauses Zürich. Der gebürtige Bayer greift zur Eröffnung am 19. September 2025 gleich selbst in die Tasten: Der studierte Pianist und Volkswirt begleitet die Mezzosopranistin Elīna Garanča bei ihrem Liedrezital. Dafür zieht er von Berlin nach Zürich. Ob er auch seine fünf Töchter für den Umzug begeistern kann? Fest steht: Derzeit lernt er noch Schweizerdeutsch und geniesst – neben der intensiven Planung für die kommenden Spielzeiten – die Nähe zu den Bergen und zum See. Irma Frei (84) wurde als Jugendliche ins Heim eingewiesen und kurz darauf zur Zwangsarbeit verpflichtet – und das nur, weil sich ihre Eltern damals trennten. Erst mit Erreichen der Volljährigkeit, die damals bei 20 Jahren lag, wurde Irma Frei in die Freiheit entlassen. Für drei Jahre harter Schichtarbeit erhielt sie zum Schluss lediglich 50 Franken. Später arbeitet sie als Fotomodell und Verkäuferin in einer Herrenboutique. Jahrzehntelang schweigt sie über dieses Kapitel ihres Lebens, weder ihr Mann noch ihre zwei Töchter wissen Bescheid – bis sie mit über 80 all ihren Mut zusammennimmt und ihre Geschichte öffentlich macht. ____________________ Moderation: Olivia Röllin ____________________ Das ist «Persönlich»: Jede Woche reden Menschen über ihr Leben, sprechen über ihre Wünsche, Interesse, Ansichten und Meinungen. «Persönlich» ist kein heisser Stuhl und auch keine Informationssendung, sondern ein Gespräch zur Person und über ihr Leben. Die Gäste werden eingeladen, da sie aufgrund ihrer Lebenserfahrungen etwas zu sagen haben, das über den Tag hinaus Gültigkeit hat.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über zwei gelungene Börsengänge, einen weiteren Tiefschlag für Bayer und einen Absturz bei Tui. Außerdem geht es um Etoro, Pfisterer Holding, Super Micro, AMD, Nvidia, Coreweave, Cisco, Eon, Daimler Truck, Brenntag, Renk, Hapag Lloyd, Baidu, WeRide, Uber, General Motors, Mercedes-Benz, BMW, Volkswagen, Pony.AI, Momenta Technology, Tesla, Alphabet, Archer Aviation, Marvell Technology, Broadcom, The Trade Desk, Datadog, MongoDB, Adobe, Diamondback Energy, Regeneron Pharmaceuticals, Warner Bros Discovery, Rheinmetall, Siemens Energy. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

"Een opvallende set met cijfers", zegt Stan Westerterp van Bond Capital Partners naar aanleiding van de resultaten van ABN Amro. "De voorzieningen voor oninbare leningen vielen mee en de rentes zijn ook alweer een tijd wat hoger, dus de marges daar zijn veel beter dan een aantal jaren geleden. Ook de kapitaalratio's zijn sterk en ze keren een aardig dividend uit." De hypotheekmarkt is voor ABN Amro heel belangrijk en daar kijkt Joost van Leenders van Van Lanschot Kempen kritisch naar. "Er is daar wel meer volume, maar daar zit wel druk op de marges, de concurrentie is daar toegenomen." Joost vraagt af de rentemarges in de nabije toekomst nog verder kunnen verbeteren "Tijdelijk positief", dat is Stans oordeel over het beurssentiment. Zeker als je kijkt naar hoe april begon: in mineur, na Trumps aankondiging van de handelstarieven. Of het herstel helemaal realistisch is, maar vooralsnog is het goed. Joost tekent daarbij aan dat we alweer richting all time highs gaan. Verder in de podcast aandacht voor de laatste economische ontwikkelingen en de cijfers van onder andere Walmart, Cisco, Bayer en Tencent. Uiteraard behandelen we de luisteraarsvragen en geven de experts hun tips. Joost tipt een Amerikaans bedrijf in de medische sector, Stan tipt een Nederlands industrieel concern. Geniet van de podcast! VanEck ETF’s (advertorial) Deze week is ook weer het tweewekelijks gesprek te beluisteren met Martijn Rozemuller, ceo van VanEckETF’s, de partner van BeursTalk. Met Martijn ga ik in op de toegenomen volatiliteit in de markt en hoe je daar als ETF-belegger mee omgaat. Hoewel VanEck geen specifieke low volatility ETF's heeft, zijn er wel degelijk ETF's bij VanEck te vinden die bescherming bieden. Martijn wijst daarbij in eerste instantie naar de Multi Asset ETF's, die variëren in risico. Je vindt ze hier, hier en hier. Daarnaast heeft VanEck vier MOAT-ETF's, dat zijn ETF's die beleggen in gedegen, grote bedrijven met een zeer goede staat van dienst die bovendien aantrekkelijk gewaardeerd zijn. Bekijk hier de informatie over de VanEck Morningstar US ESG Wide Moat UCITS ETF, de VanEck Morningstar US Wide Moat UCITS ETF, de VanEck Morningstar US SMID Moat UCITS ETF en de VanEck Morningstar Global Wide Moat UCITS ETF. VanEck heeft mede vanwege de succesvolle MOAT-ETF's de Gouden Stier gewonnen voor Beste ETF-aanbieder! Martijn vertelt je er alles over, blijf dus luisteren tot na de disclaimer. Geniet van de podcast! De gepresenteerde informatie door VanEck Asset Management B.V. en de aan haar verbonden en gelieerde bedrijven (samen "VanEck") is enkel bedoeld voor informatie en advertentie doeleinden aan Nederlandse beleggers die Nederlands belastingplichtig zijn en vormt geen juridisch, fiscaal of beleggingsadvies. VanEck Asset Management B.V. is een UCITS-beheerder. Loop geen onnodig risico. Lees de Essentiële Beleggersinformatie of het Essentiële-informatiedocument. Meer informatie? https://www.vaneck.com/nl/nl/See omnystudio.com/listener for privacy information.

Sermonette delievered on Monday after Low Sunday, 2025, in Paris during a Pilgrimage to France, by Rev. Tobias Bayer.

Sermonette delivered on the Wednesday after Low Sunday, 2025, in Paris during a Pilgrimage to France, by Rev. Tobias Bayer.

Sermonette delievered on Tuesday after Low Sunday, 2025, in Paris during a Pilgrimage to France, by Rev. Tobias Bayer.

Sermon delievered on Low Sunday, 2025, in Paris during a Pilgrimage to France, by Rev. Tobias Bayer. Epistle: 1 John 5, 4-10. Gospel: St. John 20, 19-31.

Sermonette delievered on Easter Saturday, 2025, in Paris during a Pilgrimage to France, by Rev. Tobias Bayer.

Sermonette delivered on Easter Friday, 2025, in Paris during a Pilgrimage to France, by Rev. Tobias Bayer.

Sermonette delivered on Easter Thursday, 2025, in Paris during a Pilgrimage to France, by Rev. Tobias Bayer.

Sermonette delivered on Easter Wednesday, 2025, in Paris during a Pilgrimage to France, by Rev. Tobias Bayer.

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Accreditation/Credit Designation Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours. Instructions on How to Receive Credit Listen to this podcast in its entirety. Go to gotoper.com/credit and enter code: 6947 Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate. Today's faculty are: Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research HCI Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Disclosures: Grant/Research Support (paid to institution): Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Merck, Nektar, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, Seagen, Takeda, Tra-con Himisha Beltran, MD Associate Professor of Medicine Director of Translational Research Within Medical Oncology Harvard Medical School Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology Dana Farber Cancer Institute Boston, MA Disclosures: Grant/Research Support: Circle Pharma, Daiichi Sankyo, Novartis; Adviser: Amgen, AstraZeneca, Daiichi Sankyo, Novartis Maha Hussain, MD, FACP, FASCO Genevieve E. Teuton Professor of Medicine Professor, Medicine (Hematology/Oncology) Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL Disclosures: Advisory Board: AstraZeneca, Bayer, Convergent Therapeutics, Honoraria: AstraZeneca, Bayer The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity. Release Date May 14, 2025 Expiration Date May 14, 2026

Blanchard Valley Health System CEO Myron Lewis explains his concern about state and federal proposals that he says would put patients' care at risk (at 14:05) --- As we head into the season of fun in the sun, it's time for a reminder about the dangers of skin cancer... and new technology that could make treatment more accessible and less invasive (at 25:27) --- For the 10th year, Bayer is the presenting sponsor of country music superstar Luke Bryan's Farm Tour, raising awareness for the issue of food insecurity and the challenges faced by the people who put meals on our table (at 46:23)

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Bayer has announced a restructuring that will result in 2,000 job cuts and a reduction in management layers. CEO Bill Anderson believes Trump's most favored nations policy could provide an opportunity for European countries to contribute more to biopharma innovation. Galapagos has abandoned plans for a spinout and cell therapy, causing a stir in the industry. Trump's most favored nation policy has led to a sell-off of PBMs, but analysts believe it may not have a significant impact without further congressional action. Sino Biological offers solutions for autoimmune diseases, with reagents for nearly 50 different conditions. In other news, CMS is preparing for a new cycle of drug negotiations, Azafaros has raised $150 million for rare neuro-metabolic diseases, and Roche's Genentech is investing $700 million in a North Carolina plant. 10x Genomics has cut 8% of its workforce, and there are upcoming webinars on biotech downturns and AI in life science R&D. Job opportunities include positions at 4D Molecular Therapeutics, Takeda, and Regeneron Pharmaceuticals.

Bayer sorprendió al mercado con sus resultados del primer trimestre. La compañía farmacéutica registró un descenso en el beneficio neto del 35%, el cual se vio impactado por cargos extraordinarios ligados a litigios y reestructuraciones. Su beneficio operativo ajustado cayó también un 7%, donde superó por poco los 4.000 millones de euros. Sin embargo, el consenso de analistas esperaba una cifra peor. Los expertos auguraban una disminución menor, de 3.750 millones de euros. Seguramente por esto, las acciones de la compañía llegaron en momentos a superar el 10%. Otra de los aspectos que más gustó al mercado fueron las previsiones que realizó la empresa. Primero, con la del beneficio operativo ajustado, donde la compañía espera unas cifras que se situarán entre entre 9.300 y 9.800 millones de euros. Segundo, con los aranceles, en la que la empresa pronostica que podrá compensar los efectos. Uno de los aspectos más positivos de los resultados de Bayer fue la facturación, que se mantuvo estable en este período y alcanzó los 137000 millones de euros. Uno de los negocios más deficitarios para la farmacéutica ha sido su división agrícola Crop Science. Obtuvo un beneficio de un 10% inferior al trimestre del año anterior. La compañía no es ajena a estos resultados decepcionantes y por ello realizará una reorganización en Alemania, centrándose en la producción y la investigación en protección de cultivos y en productos específicos que vayan más allá de los genéricos. Así valoraba el impacto negativo de Crop Science, Un entorno que puede ser aún más difícil después de las palabras de Donald Trump del lunes, en el que aseguró que los europeos tenían que pagar más por los medicamentos. Con esto, el presidente estadounidense pretende rebajar los precios un 80%. Bayer es una empresa químico-farmacéutica alemana fundada en Barmen, Alemania en 1863, aunque al principio era una fábrica de tintes. Friedrich Bayer y su socio, Johann Friedrich Weskott, se dan cuenta que que el tinte contiene algún medio curativo, descubriendo casi por accidente la aspirina, por la cual es conocida mundialmente en todo el mundo. Fue en 1899 cuando la registra por primera vez.

Send us a textFood insecurity affects more than 47 million Americans – but this spring Bayer is once again teaming up with country superstar, Luke Bryan to help fight hunger and support the local farmers who put food on our tables.For the 10th year, Bayer will be the presenting sponsor of Luke Bryan's annual Farm Tour and will be continuing their impactful #herestothefarmer and ‘Take Care, Now' campaigns.From Bayer, Brian Leake, Director of External Communications joins me to discuss this important partnership.https://www.lukebryan.com/farm-tour-2025

President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of the Most Favored Nation rule he attempted to introduce in his first term. The rule would essentially link U.S. prices to those paid in other nations where medications are cheaper. Biopharma reaction was one of tentative relief, with BMO Capital Markets analysts suggesting the executive order had “more bark than bite.” Meanwhile, the Centers for Medicare and Medicaid Services announced that among the next 15 drugs to undergo IRA-prescripted price negotiations could be drugs payable through Medicare Part B, and not just Part D, where the first two rounds have applied.  Into all of this action steps Vinay Prasad, the outspoken oncologist and hematologist who was named last week as the next director of the FDA's Center for Biologics Evaluation and Research. While the S&P Biotech ETF fell by more than 5% upon the news, overall reaction was fairly measured, with cell and gene therapy executive Audrey Greenberg summing up Prasad's selection as “anything but a status quo appointment.”  Over in the weight loss and obesity space, Eli Lilly can't seem to lose. This weekend, Lilly announced full data from a head-to-head trial showing a “superior benefit-to-risk ratio” for its Zepbound over Novo Nordisk's Wegovy. And last week, the Indiana-based pharma won a court battle against compounders when a judge sided with the FDA, stating that tirzepatide—the active ingredient in both Zepbound and diabetes sister drug Mounjaro—was no longer in shortage. Add on a presidential shoutout during Trump's Monday press conference for its U.S. manufacturing investments, and it really was Lilly's week.  Flying less high are some 2,000 Bayer employees who lost their jobs in the first quarter of 2025 as part of the company's new operating model, which is intended to make Bayer “much more agile.” On a less direct flight is Galapagos, which reversed course on plans to spin out a portion of the company and find a new CEO. Instead, CEO Paul Stoffels will make a quicker exit and the Belgian biotech could sell off its cell therapy assets as it looks to build up a new pipeline in house, having abandoned the spinout idea altogether. Stay tuned.  Finally, in ClinicaSpace this week, we took a deep dive into the HIV treatment space, where companies like Gilead and Immunocore are targeting a cure, while the Trump administration slashes funding for HIV research.  

Today's guest is Patricio La Rosa, Head of End-to-End Decision Science at Seed Production Innovation in Bayer Crop Science. With over 20 years of experience developing AI and data science solutions across healthcare and agriculture, Patricio joins Emerj Managing Editor Matthew DeMello to explore how machine learning can drive better outcomes across the drug development lifecycle, from research design to clinical deployment. Patricio discusses how AI is optimizing early trial planning, improving participant engagement, and supporting ethical, human-centered decisions at scale. Drawing lessons from both agriculture and life sciences, he emphasizes the importance of connecting technical models with real-world workflows. The conversation also delves into key barriers to AI adoption in clinical settings, including behavioral friction, model transparency, and challenges in orchestrating decision-making across global teams. Patricio offers a grounded perspective on what it takes to move from experimentation to enterprise impact in AI-driven R&D. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast!

APAC stocks traded mostly higher following the rally on Wall St owing to the US-China trade war de-escalation after both sides agreed to cut tariffs by 115ppts for an initial period of 90 days, although some of the gains were capped as the euphoria began to moderate.White House Executive Order said US will cut the minimum tariff on China shipments from 120% to 54%, and a minimum flat fee of USD 100 is to remain.DXY took a breather and gave back some of yesterday's firm gains; 10yr UST futures traded rangebound after recently suffering from a lack of haven appealEuropean equity futures indicate a lower cash market open with Euro Stoxx 50 futures down 0.2% after the cash market finished with gains of 1.6% on Monday.Looking ahead, highlights include UK Jobs, German ZEW, US CPI, Speakers include US President Trump, BoE's Pill, Bailey & ECB's Rehn, Supply from Netherlands, UK, Italy & Germany, Earnings from JD.Com, Intuitive Machines, On, Munich Re, Hannover Re, Bayer, K+S, Leg, Ferrovial & A2A.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, Lilly's Zepbound has been found to have a superior benefit-risk ratio compared to Novo's Wegovy, BMS and Sanofi settle a Plavix lawsuit with Hawaii for $700 million, and biopharma companies are focusing on developing a cure for HIV as federal funding for related research is being cut. Sino Biological offers comprehensive solutions for autoimmune diseases, and Roche promises a $300 million investment in China production after a multibillion-dollar investment in the US. On the other hand, Lexeo and IGM have both announced significant layoffs. Novartis CEO has expressed concerns about Trump's pricing controls.Funding for HIV-related research and infrastructure is being cut by the Trump administration, leading biopharma companies like Gilead and Immunocore to focus on finding a cure for HIV. In the field of neurology, there is a need for more precise diagnostic tools to effectively treat neurodegenerative conditions. The new HHS vaccine requirement has been criticized by leading vaccine physician Paul Offit as potentially being anti-vaccine activism disguised as policy. Companies like Novartis, Bayer, and AstraZeneca are exploring new indications and innovations in radiopharmaceuticals, hoping to capitalize on a market that could reach $16 billion by 2033. The FDA has faced delays in reviewing certain drugs, while biotech stocks have fallen after the appointment of Vinay Prasad to succeed Marks at CBER. Vertex has decided to abandon AAV in the gene therapy space.Upcoming events include a webinar on surviving and thriving in the biotech downturn. Job opportunities in the biopharma industry include positions at Takeda, Daiichi Sankyo, and AbbVie. Heather McKenzie, senior editor at BioSpace, is open to suggestions for future coverage topics in neuroscience, oncology, cell & gene therapy, metabolic, or other areas.

Josep Prats, gestor de Abante Asesores, vigila el comportamiento de Bayer, Munich Re, Vonovia y Commerzbank.

Glyphosate is a toxic carcinogenic chemical found in RoundUp, a weedkiller that is routinely sprayed on our lawns and crops. But the bad news doesn't stop there! It is making its way into the food we eat, the air, and the water. Worse still, the maker of glyphosate, Bayer, is working on passing liability shield legislation so that they cannot be sued for the way the poison in their products is affecting the nation! Today, Kelly Ryerson, known as the Glyphosate Girl, explains why she is working so hard to inform the public about the dangers of glyphosate and the company that wants to protect itself from the fallout of the harm it is causing. Kelly goes over the legislation that is being considered in various states across the country. She also explains why glyphosate is so damaging, how it personally affected her own life, and how a General Mills whistleblower helped her to connect the dots about it all. Update: The liability legislation being considered in North Dakota, at the time of the interview, has since been passed in that state.   Visit Kelly's websites: americanregeneration.org and glyphosatefacts.com Become a member of the Weston A. Price Foundation (and use the code pod10) Check out our sponsors: Arvoti and Lumiram

Why is the timing of a fungicide application so important?  Dr. Megan Taylor is in the podcast room with our hosts Jeff Jarrett and Sal Sama for this episode of The High Ground powered by Premier Companies.  Dr. Taylor is the Technical Agronomist at Bayer, and as a fun fact, she is a former colleague of Sal's!Dr. Taylor will share about her educational background and what eventually led to her working for Bayer.  You'll learn about the changes that have occurred in the world of fungicides over the last decade including emerging diseases and how planting practices have changed application needs.  You'll learn about best application practices for growers who need to cover a lot of acres and what will give you the biggest bang for your buck to protect your yield potential.  Struggling with stink bugs not just in your field but in your home as well?  Dr. Taylor will share her thoughts on those as well, and if you are looking for fungicide data, head on over to the wealth of knowledge at https://cropprotectionnetwork.org/.

Why is the timing of a fungicide application so important?  Dr. Megan Taylor is in the podcast room with our hosts Jeff Jarrett and Sal Sama for this episode of The High Ground powered by Premier Companies.  Dr. Taylor is the Technical Agronomist at Bayer, and as a fun fact, she is a former colleague of Sal's!Dr. Taylor will share about her educational background and what eventually led to her working for Bayer.  You'll learn about the changes that have occurred in the world of fungicides over the last decade including emerging diseases and how planting practices have changed application needs.  You'll learn about best application practices for growers who need to cover a lot of acres and what will give you the biggest bang for your buck to protect your yield potential.  Struggling with stink bugs not just in your field but in your home as well?  Dr. Taylor will share her thoughts on those as well, and if you are looking for fungicide data, head on over to the wealth of knowledge at https://cropprotectionnetwork.org/.

In Hamburg fehlt ganz viel Rasen, und auf Ibiza turnen die Bayern rum: War doch wieder viel los in Fußball-Deutschland. Über den Aufstieg des HSV sprechen Mario und Matthias mit Reporter Sebastian Wolff. Außerdem im Programm: Lukas Schönmüller war für DAZN in Leverkusen und berichtet von Xabi Alonsos Abschied. Wie geht es bei Bayer weiter? Was passiert mit Wirtz? Wird der BVB jetzt Vierter oder macht er BVB-Sachen? Und natürlich blickt Mario noch zurück auf das emotionale Servus von Thomas Müller. Hört rein!

Jordi Sánchez, CEO de Bayer Iberia, detalla la estrategia de la multinacional, su inversión en I+D y el compromiso con la sostenibilidad en España.

Jordi Sánchez, CEO de Bayer Iberia, detalla la estrategia de la multinacional, su inversión en I+D y el compromiso con la sostenibilidad en España.

Bayer Leverkusen and Borussia Dortmund meet in a heavyweight Bundesliga fixture on Sunday, but only one of these teams is in need of the points.Bayer's title defence is now over after Bayern Munich wrapped up the league crown with a few games to spare and they have secured second spot irrespective of what happens in their final two games.In contrast, Dortmund have it all to play for as they sit in fifth spot but are just one point behind Freiburg in fourth.

This week's episode includes coverage from our team in Washington D.C. and an interview with an entrepreneur with over ten years in the soil health business. Our D.C. coverage includes insights and quotes from U.S. Secretary of Agriculture Brooke Rollins, EPA Administrator Lee Zeldin, NRCS Chief Aubrey J.D. Bettencourt, and USDA Chief Meteorologist Brad Rippey. Topics include recent U.S. trade wins, the latest developments on the Waters of the U.S. rule, government downsizing or what guests referred to as rightsizing and yet another delay in the Farm Bill markup. We also report on a new economic impact study on the biomass-based diesel industry and Bayer's decision to exit the seed treatment equipment market. In this month's interview, we hear what led Landom Oldham from Heartland Soil Services to starting the company over 10 years ago, the risks he had to take and how soil health awareness among farmers has grown. Oldham did not grow up on a farm, but now is actively involved in the agriculture industry and provides a planting update from the Kansas area. Stay connected with us for more agriculture content on Instagram, TikTok, Facebook, and YouTube, along with our weekly videos!

Andrea Picciotti-Bayer, Director of the Conscience Project, talks about a new law passed in the state of Washington that forces priests to break the seal of the confessional. Watch a short video about St. John Seminary's Online in M.A. in Pastoral Ministry Program: https://vimeo.com/79053099If you are interested in learning more about the online M.A. in Pastoral Ministry Program for lay students at St. John's Seminary, email Dr. Stuart Squires at mapm@stjohnsem.eduListen to the previous episode with Andrea: https://open.spotify.com/episode/4M36YkzQAAixeDCk3rhy3G?si=QqpVdDeCTZmf3hpAZmdBGw

Send us a textIs an Indian CDMO the right move for your biologics CMC development?Pulling back the curtain on what might be your next strategic manufacturing advantage, this episode reveals the hidden capabilities emerging from India that leading biotech companies are racing to access. As supply chain vulnerabilities continue to expose risks in traditional manufacturing models, could the solution lie halfway around the world?Joining us to reveal the inside story is Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions and veteran of global pharma giants like Bayer, Merck and Lonza. With over 20 years in biotech, Abdelaziz brings unique insights on when and why you might want to look beyond traditional Western manufacturing partners. Our host, David Brühlmann, leverages his 15+ years of biotech industry experience to extract the practical insights you need to make informed decisions about your manufacturing strategy.In this second segment, we'll dive deeper into the Indian CDMO and biomanufacturing landscape. Then we'll explore Lupin's specialized capabilities and finally extract Abdelaziz's most valuable leadership insight from his role as a CEO.Key insights from this episode:The One-Stop Solution Advantage: Discover how Lupin is building rare end-to-end manufacturing capabilities for complex modalities like Antibody-Drug Conjugates (ADCs) - potentially eliminating the headache of managing multiple manufacturing partners across continents.Beyond Labor Cost Advantages: "Digitalization plays a key role, especially if you are operating in a cost-competitive space," explains Abdelaziz. Learn how Indian CDMOs are strategically automating key processes to drive both efficiency and quality, challenging Western perceptions.Leadership Across Cultures: "Listen, listen, listen," emphasizes Abdelaziz when discussing cross-cultural leadership. Understand the subtle communication dynamics that can make or break a global manufacturing partnership, especially when navigating hierarchy-sensitive cultures.Whether you're actively evaluating Indian manufacturing options or simply preparing for the shifting global biotech landscape, these next several minutes deliver insights you can't afford to miss.Listen to the full episode to extract the specific capability indicators that will help you determine if and when an Indian CDMO partnership makes strategic sense for your unique biologics pipeline.Want to find out more about the CDMO selection? Here's what one of our distinguished guests had to say about it:Episodes 103-104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma MostafaConnect with Abdelaziz Toumi:LinkedIn: www.linkedin.com/in/abdelaziztoumiLupin Manufacturing Solutions: www.lupin.comNext step:Transform your process development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/callReady to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Host: Rick Grobbee Guest: Michele Brignole Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1805?r  Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Send us a textIs an Indian CDMO the right move for your biologics pipeline?As Western biotech companies seek new strategic advantages, one question keeps surfacing: Is India truly becoming the next biotech manufacturing powerhouse? And what hidden capabilities are emerging that leading companies are racing to access?In this episode of the Smart Biotech Scientist Podcast, Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions and veteran of global pharma giants like Bayer, Merck, and Lonza, joins host David Brühlmann to reveal the inside story on when and why you might want to look beyond traditional Western manufacturing partners.Here are three key insights from their conversation:The Post-Pandemic Manufacturing Revelation: "During the pandemic, we realized how vulnerable our supply chain truly is," explains Abdelaziz. Discover why diversifying manufacturing partnerships isn't just smart—it's becoming essential for resilience in an unpredictable world.Beyond the Cost Advantage: While Indian CDMOs can deliver up to 80% cost savings compared to Western counterparts, Abdelaziz reveals the unexpected advantages that make the most strategic partnerships about far more than budget considerations.The Trust Factor: "This is a business of trust," emphasizes Abdelaziz. Learn the critical questions that separate world-class Indian CDMOs from the rest, and the cultural nuances that can make or break your manufacturing partnership.Ready to discover if Indian CDMOs could be the missing piece in your biologics development strategy? Tune in for expert insights on IP protection, talent access, and how to navigate the cultural dynamics that determine success in this emerging manufacturing powerhouse.Listen to the full episode to unlock the strategic advantage that could transform your pipeline's journey from lab to market.Want to find out more about the CDMO selection? Here's what one of our distinguished guests had to say about it:Episodes 103-104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma MostafaConnect with Abdelaziz Toumi:LinkedIn: www.linkedin.com/in/abdelaziztoumiLupin Manufacturing Solutions: www.lupin.comNext step:Transform your process development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/callReady to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

The potential for real world evidence (RWE) is huge, according to enthusiasts, but to the uninitiated it can seem like a complicated and forbidding subject. In this Over the Counter double episode, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, makes understanding real world evidence easy. We start with the basics, with what it is and what companies need to know about it, and what the key difference is with randomised control trials. Many companies are already using real world evidence, Volker notes, and he extracts some key lessons for companies interested in trying it out based on his extensive experience working with industry on such projects. Timestamps 2:00 – Introductions 4:00 – What is real world evidence? 5:00 – Can RWE and clinical trials complement each other? 10:00 – Why RWE is particularly attractive today 14:00 – Don't reinvent the wheel 18:00 – Why is this important for consumer health companies? 25:00 – Why RWE is often a good value option, especially for SMEs 33:00 – Applications of RWE in consumer health Guest Bio Volker Spitzer has more than 30 years of R&D experience spanning the consumer health sector, ingredients industry, and academia. Beginning his career as a professor in pharmaceutical sciences, he ascended to global positions encompassing R&D, innovation, licensing/M&A, and medical marketing at firms like Roche, DSM Nutritional Products, and Bayer. Since October 2017, Volker has been affiliated with IQVIA Consumer Health, serving as the vice president for global R&D and RWE Services. His purview primarily includes clinical research, RWE, virtual trials, and the burgeoning field of digital health. He has penned over 80 scientific publications, whitepapers and textbooks centered on science and innovation.

Bayer Pharma Aktiengesellschaft v. Mylan Pharmaceuticals Inc.

Send us a textHealth coaching is often overlooked in healthcare, but could it be the key to improving behavior change, supporting chronic care, and filling gaps left by clinical shortages? In this episode of CareTalk: Healthcare. Unfiltered., Eugene Borukhovich, COO & Co-Founder of YourCoach, joins John Driscoll to discuss why coaching is gaining traction, how YourCoach is helping scale it, and why embracing health coaches could be critical to building a stronger, more sustainable healthcare system.

Food Tank, in partnership with the Sprouts Healthy Communities Foundation, recently hosted a special series on “Food is Medicine and Eating for Health.” This webinar features conversations from Part 1 of the event as panelists come together to discuss what it means to implement holistic approaches to improving access to healthy, nourishing foods; the empowerment of youth; and how we ensure that the opportunities presented by Food is Medicine aren't wasted. Speakers include Erika Allen, Urban Growers Collective; Dr. Kofi Essel, Elevance Health; Rachel Fisher, U.S. Department of Health and Human Services; Kathleen Merrigan, Swette Center for Sustainable Food Systems at Arizona State University; A-dae Romero-Briones, First Nations Development Institute; Alice Waters, American chef, restaurateur, and author; and Lyndsey Waugh, Sprouts Healthy Communities Foundation. Plus, hear about the staffing cuts expected at the world's largest humanitarian organization, the push for countries to release their updated climate action plans, and the new legislation that could make it harder to win a legal case against the agrochemical company Bayer.  While you're listening, subscribe, rate, and review the show; it would mean the world to us to have your feedback. You can listen to “Food Talk with Dani Nierenberg” wherever you consume your podcasts.

Mit  Rüdiger Bachmann und Christan Bayer, der die Einreise in die USA überstanden hat. US-Daten BEA: Gross Domestic Product, 1st Quarter 2025 (Advance Estimate) Bachmann et.al.: Identifying Monetary Policy Shocks Using the Central Bank's Information Set Koalitionsvertrag CDSU-Kabinettsmitglieder (designiert) Steinkühlerpause

Historic moves out of Washington D.C., as HHS Secretary Robert F. Kennedy Jr. announces his fight to find the cause of autism, and new FDA Commissioner Dr. Marty Makary takes action to remove toxic additives and dyes from our food. Jefferey Jaxen reports on the White House embracing lab leak theory, the bleak future of Bayer's Roundup, and new cancer risks associated with COVID vaccines—just as the federal government begins to reverse its stance. New Bill Makes Health History in Tennessee. Finally, retired pediatrician Dr. Paul Thomas shares his journey from vaccine advocate to whistleblower in his new book, ‘Vax Facts.'Guests: Bernadette Pajer, Dr. Paul Thomas#TheHighWire #RFKJr #MartyMakary #FoodDyeBan #VaccineSafety #COVIDVaccine #AutismAwareness #PaulThomasMD #Glyphosate #Roundup #HealthFreedom #LabLeakBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

FDA and Big Pharma Conflict of Interest (0:00) Bayer's Historical Misconduct and Glyphosate Toxicity (2:13) Health Ranger Store's Glyphosate Testing (4:54) Trump's Rejection of Netanyahu's Iran Attack Plan (6:28) Florida State University Shooting and Anti-Trump Protests (11:14) Blue Origin Rocket Launch and Media Fakery (14:29) Microscopy Analysis of Chemtrails and Heavy Metals (26:23) Incubation Results and Potential Pandemic (46:56) Call to Action and Conclusion (51:28) Preparation for a Post-Human Future (52:09) Economic Challenges and Health Ranger Store Promotions (1:16:03) Weaponization of the Air (1:20:17) Historical Context of Climate Change and Chemtrails (1:23:22) Health Implications and Defenses Against Chemtrails (1:30:45) Personal Protective Measures and Future Predictions (1:35:58) Project Paperclip and Nazi Influence in US Institutions (1:46:14) Critique of NASA and Moon Landings (2:07:46) UFOs, MJ 12, and Government Involvement (2:14:18) Health Ranger Store Product Highlights (2:28:10) For more updates, visit: http://www.brighteon.com/channel/hrreport  NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Big Pharma is under fire. A judge just rejected Johnson & Johnson's $10 billion talc settlement offer, and Bayer faces a stunning $2.1 billion loss in a Roundup lawsuit. Now, both companies are scrambling for immunity from future legal blowback across the U.S.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.